Plasma p-tau217: A Blood Test for Precision Alzheimer’s Disease Staging
A new study demonstrates that a blood-based biomarker, plasma phosphorylated tau 217 (p-tau217), can accurately reflect the pathological stages of Alzheimer’s disease as defined by positron emission tomography (PET) scans. In a cohort of 237 individuals across the Alzheimer’s spectrum, plasma p-tau217 showed excellent performance in detecting early amyloid pathology (Thal stages I-II) and intermediate tau spread (Braak stages III-IV). The research identifies specific concentration thresholds (1.895–5.077 pg/mL) that define a “therapeutic window,” offering a highly accessible and precise tool for identifying optimal candidates for emerging disease-modifying therapies.
Why it might matter to you:
This work directly advances the translational neuroscience goal of moving from complex, expensive neuroimaging to accessible blood-based diagnostics. For a researcher focused on the neurobiology of chronic conditions and treatment responses, this exemplifies a major shift towards precision biomarkers. It provides a concrete model for how a measurable biological signal can be rigorously linked to a clinical staging framework, a methodological approach relevant to modeling therapeutic interventions like placebo analgesia in chronic pain.
Stay curious. Stay informed — with
Science Briefing.
Always double check the original article for accuracy.